Structure-based design of glycopeptides with applications in cancer therapy and diagnosis

Conference title: Structure-based design of glycopeptides with applications in cancer therapy and diagnosis

Summary:

MUC1, a glycoprotein overexpressed in cancer cells and exhibiting abnormal glycosylation, has emerged as a potential target for cancer vaccine development.¹ The presence of anti-MUC1 antibodies has also been observed in the early stages of cancer.² In this presentation, we will explore the use of structured-guided designed MUC1 glycopeptides containing unnatural amino acids and/or carbohydrates as cancer vaccines and diagnostic tools for different cancer types. To illustrate the versatility of these compounds, we will present the results of vaccines testing on mice in our lab and introduce a new biosensor that can effectively distinguish between pancreatic cancer patients and healthy individuals, showing higher sensitivity and specificity compared to other clinically used biomarkers.^3-5

References

[1] M. A. Hollingsworth, and B. J. Swanson, Nat. Rev. Cancer 2004, 4, 45.

[2] Chen, H.; Qian, J.; Werner, S.; Cuk, K.; Knebel, P.; Brenner, H. Clin. Epidemiol. 2017, 9, 517-526

[3] N. Martinez-Saez, N. T. Supekar, M. A. Wolfert, I. A. Bermejo, R. Hurtado-Guerrero, J. L. Asensio, J. Jimenez-Barbero, J. H. Busto, A. Avenoza, G. J. Boons, J. M. Peregrina, and F. Corzana, Chem. Sci. 2016, 7, 2294.

[4] I. Companon, A. Guerreiro, V. Mangini, J. Castro-Lopez, M. Escudero-Casao, A. Avenoza, J. H. Busto, S. Castillon, J. Jimenez-Barbero, J. L. Asensio, G. Jimenez-Oses, O. Boutureira, J. M. Peregrina, R. Hurtado-Guerrero, R. Fiammengo, G. J. L. Bernardes, F. Corzana, J. Am. Chem. Soc. 2019, 141, 4063.

[5] I. A. Bermejo, C. D. Navo, J. Castro-López, A. Guerreiro, E. Jiménez-Moreno, E. M. Sánchez Fernández, F. García-Martín, H. Hinou, S.-I. Nishimura, J. M. García Fernández, C. O. Mellet, A. Avenoza, J. H. Busto, G. J. L. Bernardes, R. Hurtado-Guerrero, J. M. Peregrina, F. Corzana, Chem. Sci. 2020, 11, 3996.